Hensley ML - Search Results

1

Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.

Hensley ML, Peterson B, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Hensley ML, et al. J Clin Oncol. 2000 Mar;18(6):1301-8. doi: 10.1200/JCO.2000.18.6.1301. J Clin Oncol. 2000. PMID: 10715301

2

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG. Hensley ML, et al. J Clin Oncol. 1999 Oct;17(10):3333-55. doi: 10.1200/JCO.1999.17.10.3333. J Clin Oncol. 1999. PMID: 10506637

3

Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.

Gemignani ML, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR. Gemignani ML, et al. Among authors: hensley ml. Gynecol Oncol. 2001 Jan;80(1):16-20. doi: 10.1006/gyno.2000.6012. Gynecol Oncol. 2001. PMID: 11136563 Clinical Trial.

4

Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.

Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, Almadrones L, Chi D, Spriggs D. Hensley ML, et al. Gynecol Oncol. 2001 Jun;81(3):485-9. doi: 10.1006/gyno.2001.6185. Gynecol Oncol. 2001. PMID: 11371143

5

The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.

Hensley ML, Hoppe B, Leon L, Sabbatini P, Aghajanian C, Chi D, Spriggs DR. Hensley ML, et al. Gynecol Oncol. 2001 Sep;82(3):464-9. doi: 10.1006/gyno.2001.6299. Gynecol Oncol. 2001. PMID: 11520141

6

Identification of prognostic factors in advanced epithelial ovarian carcinoma.

Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Chi DS, et al. Among authors: hensley ml. Gynecol Oncol. 2001 Sep;82(3):532-7. doi: 10.1006/gyno.2001.6328. Gynecol Oncol. 2001. PMID: 11520151

7

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.

Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C, Soslow R, Markman M, Hoskins WJ, Spriggs D. Barakat RR, et al. J Clin Oncol. 2002 Feb 1;20(3):694-8. doi: 10.1200/JCO.2002.20.3.694. J Clin Oncol. 2002. PMID: 11821450

8

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR. Dizon DS, et al. Among authors: hensley ml. J Clin Oncol. 2002 Mar 1;20(5):1238-47. doi: 10.1200/JCO.2002.20.5.1238. J Clin Oncol. 2002. PMID: 11870166

9

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Scheuer L, et al. J Clin Oncol. 2002 Mar 1;20(5):1260-8. doi: 10.1200/JCO.2002.20.5.1260. J Clin Oncol. 2002. PMID: 11870168

10

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Hensley ML, et al. J Clin Oncol. 2002 Jun 15;20(12):2824-31. doi: 10.1200/JCO.2002.11.050. J Clin Oncol. 2002. PMID: 12065559 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

179 results

Search Page